Consun Pharmaceutical Group Limited (Consun Pharma) reported to the Hong Kong Stock Exchange that it repurchased 305,000 ordinary shares on 10 September 2026 via on-market transactions. The buybacks were executed within a price range of HKD 12.87 to HKD 13.16 per share, resulting in a volume-weighted average cost of HKD 13.11 and a total outlay of HKD 4.00 million.

Prior to the transaction, Consun Pharma had 839.05 million issued shares (excluding treasury shares). Post-repurchase, the outstanding share count fell by 0.04% to 838.74 million, while treasury shares increased from 2.50 million to 2.80 million. Total issued shares remained unchanged at 841.55 million, as the repurchased stock is being held in treasury rather than cancelled.

The purchase was conducted under the general mandate approved by shareholders on 26 May 2026, which permits the company to repurchase up to 84.12 million shares. Including the latest transaction, Consun Pharma has repurchased 2.46 million shares to date—equivalent to 2.92% of the issued share base at the time the mandate was granted—leaving roughly 81.66 million shares still available for repurchase.

Pursuant to Hong Kong listing rules, the company is restricted from issuing new shares or disposing of treasury stock for 30 days following the buyback, establishing a moratorium that lasts until 10 October 2026.